Loading...
GRCE logo

Grace Therapeutics, Inc.NasdaqCM:GRCE Stock Report

Market Cap US$41.2m
Share Price
n/a
1Y-17.4%
7D10.6%
1D-0.8%
Portfolio Value
​
View

Grace Therapeutics, Inc.

NasdaqCM:GRCE Stock Report

Market Cap: US$41.2m

Grace Therapeutics (GRCE) Stock Overview

Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. More details

GRCE fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 98.5% below our estimate of its fair value

Earnings are forecast to grow 56.39% per year

Earnings have grown 10.5% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been diluted in the past year

Volatile share price over the past 3 months compared to the US market

Does not have a meaningful market cap ($41M)


GRCE Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW501,452 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
501,452 investors already sharing narratives
View all narratives

Grace Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Grace Therapeutics
Historical stock prices
Current Share PriceUS$2.51
52 Week HighUS$5.18
52 Week LowUS$1.79
Beta0.37
1 Month Change9.13%
3 Month Change-29.69%
1 Year Change-17.43%
3 Year Change5.46%
5 Year Change-89.97%
Change since IPO-99.57%

Recent News & Updates

Analysis Article • Jun 06

We're Keeping An Eye On Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Recent updates

Analysis Article • Jun 06

We're Keeping An Eye On Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 19

Companies Like Grace Therapeutics (NASDAQ:GRCE) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Sep 02

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Apr 20

We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 14

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • May 10

We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 11

Acasti Pharma GAAP EPS of -$0.10

Acasti Pharma press release (NASDAQ:ACST): Q1 GAAP EPS of -$0.10. Cash, cash equivalents and short-term investments of $38.4M. Given certain cost savings and overall efficiencies implemented across the organization, management believes that it now has sufficient capital to fund operations through at least March 2024, allowing for the advancement of GTX-104 through Phase 3 and advancing GTX-102 and GTX-101 to key value inflection points. The company remains on track to initiate the PK bridging study of GTX-102 in the third calendar quarter of 2022 and is expected to report out topline results on schedule before the end of calendar 2022. Assuming the PK bridging study meets its primary endpoint, and based on the FDA’s subsequent guidance, the Company plans to conduct a Phase 3 safety and efficacy trial in Ataxia Telangiectasia (A-T) patients. The Phase 3 study is expected to be initiated in the second half of calendar 2023.

Shareholder Returns

GRCEUS PharmaceuticalsUS Market
7D10.6%3.0%-0.7%
1Y-17.4%50.6%20.3%

Return vs Industry: GRCE underperformed the US Pharmaceuticals industry which returned 47.9% over the past year.

Return vs Market: GRCE underperformed the US Market which returned 20.2% over the past year.

Price Volatility

Is GRCE's price volatile compared to industry and market?
GRCE volatility
GRCE Average Weekly Movement15.7%
Pharmaceuticals Industry Average Movement9.3%
Market Average Movement7.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: GRCE's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: GRCE's weekly volatility has increased from 10% to 16% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20025Prashant Kohliwww.gracetx.com

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN).

Grace Therapeutics, Inc. Fundamentals Summary

How do Grace Therapeutics's earnings and revenue compare to its market cap?
GRCE fundamental statistics
Market capUS$41.17m
Earnings (TTM)-US$7.79m
Revenue (TTM)n/a
0.0x
P/S Ratio
-5.2x
P/E Ratio

Is GRCE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GRCE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$7.79m
Earnings-US$7.79m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.48
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did GRCE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 08:13
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Grace Therapeutics, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Mayank MamtaniB. Riley Securities, Inc.
Douglas LoeCantor Fitzgerald Canada Corporation